scholarly journals The femur too short? 1373 fetuses with short femur during second-trimester screening

Author(s):  
Ulrike Friebe-Hoffmann ◽  
Larissa Dobravsky ◽  
Thomas W. P. Friedl ◽  
Wolfgang Janni ◽  
Alexander J. Knippel ◽  
...  

Abstract Purpose A short fetal femur in prenatal diagnosis might be an indicator for intrauterine growth retardation (IUGR), a genetically determined small child (SGA) with or without associated fetal malformations and/or an adverse fetal outcome. Methods 1373 singleton pregnancies with a femoral length < 5th percentile detected between 1999 and 2015 during second-trimester screening in a tertiary prenatal diagnostic center were subjected to a descriptive retrospective analysis with regard to fetal characteristics as well as pregnancy outcome. Results 685 (49.9%) fetuses presented an isolated short femur, while 688 (50.1%) showed additional abnormalities. 293 (42.6%) of those were SGA babies without any malformation, while 395 (57.4%) had one or more severe anomaly of the following organ systems: 157 (11.5%) cardiovascular, 101 (7.4%) musculoskeletal, 82 (6.0%) urogenital, 72 (5.2%) cerebrocephalic, 50 (3.6%) gastrointestinal, and 5 (0.4%) thoracic. 75 (5.5%) of the fetuses showed chromosomal aberrations of which Trisomy 13, 18 and 21 were found in 2, 13 and 27 of the cases, respectively. Fetuses with associated malformations had a significantly lower live birth rate than those without (64.2% vs. 98.1%, p < 0.001); in addition, a higher rate of preterm births 36.6% vs. 11.3%, p < 0.001) and SGA babies (51.4% vs. 30.4%, p < 0.001) were observed in the first collective. Conclusion Diagnosis of a short fetal femur should lead to an extended organ screening; in the case of associated abnormalities, additional genetic testing has to be offered, as well as intensified pregnancy monitoring in pregnancies at risk for IUGR and/or preterm birth.

2012 ◽  
Vol 40 (S1) ◽  
pp. 264-264
Author(s):  
E. Colantuono ◽  
F. D'Antonio ◽  
M. Recchi ◽  
L. Marrone ◽  
B. Matarrelli ◽  
...  

2014 ◽  
Vol 34 (11) ◽  
pp. 1099-1105 ◽  
Author(s):  
D. G. Iliescu ◽  
M. L. Cara ◽  
S. Tudorache ◽  
P. Antsaklis ◽  
L. V. Novac ◽  
...  

2021 ◽  
Vol 58 (S1) ◽  
pp. 175-175
Author(s):  
B. Deloison ◽  
G. Benoit ◽  
C. Bernabe Dupont ◽  
A. Sabine ◽  
F. Jacquemard ◽  
...  

2020 ◽  
Author(s):  
AYSE OZBAN

Abstract Objective: This study aims to determine whether it is possible to predict preeclampsia by comparing postpartum results and test results of the pregnant women diagnosed with preeclampsia, whose first and/or second trimester screening tests were accessible, and to demonstrate the predictability of severity and week of onset.Background: 204 patients underwent renal transplantation in our center and 84 of them were female. Five of our patients (one of them had two births) gave birth to a total of 6 pregnancies.Method: 135 patients were diagnosed with preeclampsia and their first and/or second trimester screening tests were accessible, and 366 control participants gave birth to a healthy baby between 37-41 weeks after standard follow-up period for pregnancy and their screening tests were also accessible.Results: The study results show that the first trimester maternal serum PAPP-A level is significantly low in preeclamptic pregnant women, and that the second trimester maternal serum AFP and hCG levels are significantly high and uE3 levels are significantly low The results also suggest that the first and second trimester Down syndrome biochemical markers can be used in preeclampsia screening.Conclusion: Among these markers, uE3 is the parameter which affects the possibility of preeclampsia the most. However, the first and second trimester Down syndrome biochemical markers are not effective in predicting the severity and onset week of preeclampsia.


Sign in / Sign up

Export Citation Format

Share Document